|Videos|October 24, 2022
Clinical Trial Data on TILs in Non-Small Cell Lung Cancer (NSCLC)
Author(s)Ben Creelan, MD
In the second installment of the series, Ben Creelan, MD, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
Trispecifics: A New Strategy to Prevent Antigen Escape
5